![]() |
CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ |
Journals - Article | |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Česky / Czech version | Vnitř. Lék., 50, 2004, No. 4, p. 286 - 290 |
Intensified Vitamin D
Supplementation in Osteoporosis Štefíková K., Chylová K., Krivošíková Z., Spustová V., Dzúrik R. VVZ Slovenskej zdravotníckej univerzity - Ústav preventívnej a klinickej medicíny, Bratislava, Slovenská republika, rektor prof. MUDr. Ján Štencl, CSc. |
|
Summary: Vitamin D deficiency is not possible to correct with the nutritional vitamin D doses in postmenopausal
women with decreased bone mineral density. The aim of study was to evaluated the
effectivity and safety of 15000 IU/week vitamin D administrated in 52 postmenopausal women
with osteopenia or osteoporosis. Patients were divided into two groups. Treated group was supplemented
by calcium 0.5 g/d and 25-hydroxycholecalciferol 15000 IU/week and control group was
supplemented by calcium and placebo for two months. Plasma calcium concentration did not
change in the vitamin D treated group while it decreased (p < 0.001) in the control group. Neither
calciuria nor fractional excretion of calcium changed during the treatment period. Plasma inorganic
phosphate concentration did not change in any group, but urinary inorganic phosphate
excretion increased in the vitamin D treated group (p < 0.001). The starting 25-hydroxycholecalciferol
plasma concentrations were almost at the deficiency range in both groups. The 25-hydroxycholecalciferol
plasma concentration increased substantially (p < 0.001) in the treated group, but
it remained at the starting level in control group during the treatment period. Similar plasma
concentration increase (p < 0.001) was apparent also in 1.25-dihydroxycholecalciferol. Plasma
intact parathormone concentration did not change in the vitamin D treated patients, while it
increased (p < 0.01) in the control group. None of the vitamin D treated women suffered from
hypercalcemia and mild hypercalciuria was observed in one patient. In conclusion, the study
presents an evidence on the effectiveness and safety of 15000 IU/week 25-hydroxycholecalciferol
dosage schedule.
|
|
Order this issue
|
BACK TO CONTENTS | ||
| HOME PAGE | CODE PAGE | CZECH VERSION | |
© 1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ |
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o. |
WEBMASTER |